Atanasio
Pandiella Alonso
Institució Catalana de Recerca i Estudis Avançats
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institució Catalana de Recerca i Estudis Avançats (7)
2022
-
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
Cancer research, Vol. 82, Núm. 24, pp. 4670-4679
2021
-
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108
2017
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019
-
Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity
Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651
2016
-
Targeting the EGF/HER ligand-receptor system in cancer
Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898
2014
-
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy
Journal of the National Cancer Institute, Vol. 106, Núm. 11
2013
-
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
Oncogene, Vol. 32, Núm. 11, pp. 1452-1459